2 deals
Venture capital fund · 1 deal
AbbVie Ventures
Disclosed deals
Every published round AbbVie Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| ParagenBio | Series A | 15 Aug 2018 | $6m | Lead | Techboard, SmartCompany, Brandon Capital portfolio, OneVentures portfolio, Brandon BioCatalyst portfolio |
Portfolio
Companies AbbVie Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| ParagenBio | 15 Aug 2018, Series A | 1 | 1 |
Funds
Fund closes reported for AbbVie Ventures, as distinct from the investments it has made.
Portfolio companies acquired
Companies AbbVie Ventures has backed that another company then bought. An exit for the holding, not a deal AbbVie Ventures did.
People
| Name | Role | Sources |
|---|---|---|
| Margarita Chavez | Managing Director | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Coverage
Stories naming AbbVie Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Unnamed stage
$6m
Paragen Bio launches in northern Queensland with $6 million investment
A James Cook University hookworm-research biotech, Paragen Bio, has launched with $6 million from Brandon Capital's MRCF, AbbVie Ventures and OneVentures to develop hookworm-derived medicines against autoimmune disease.
Also Brandon Capital portfolio·OneVentures portfolio·SmartCompany·Techboard